ArticleJAC-antimicrobial resistance2026
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Nacubactam is a novel diazabicyclooctane β-lactamase inhibitor with activity against PBP2 that is in clinical development with aztreonam or cefepime. The Methods: Isolates were collected as part of a surveillance study from 24 countries in Asia, Europe and North America. Susceptibility testing was by CLSI broth microdilution. Meropenem-non-susceptible Enterobacterales isolates were sequenced by nanopore technology to identify resistance mechanisms. Of 12 613 isolates collected, 630 carbapenemase-producing isolates were detected. Results: All KPC-producing (158) and OXA-48-like-producing (142) isolates were inhibited by ≤4/4 mg/L of aztreonam/nacubactam or ≤8/8 mg/L cefepime/nacubactam. Aztreonam/nacubactam at ≤4/4 mg/L was active against 98.7% of the 307 NDM-producing isolates, more than aztreonam/avibactam (95.1% susceptible) or cefiderocol [85.7% susceptible (CLSI breakpoints)], while cefepime/nacubactam was active against 94.1% at ≤8/8 mg/L. Insertions in PBP3 were present in 39/47 (83%) of NDM-positive Conclusions: Aztreonam/nacubactam and cefepime/nacubactam demonstrated potent
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.